An Integrated clinical pathway for diagnosis, treatment and care of rare diseases: model, operating procedures, and results of the project TRANSLATE-NAMSE funded by the German Federal Joint Committee

Daniela Choukair, Fabian Hauck, Markus Bettendorf, Heiko Krude, Christoph Klein, Tobias Bäumer, Reinhard Berner, Min Ae Lee‐Kirsch, Corinna Grasemann, Peter Burgard, Georg F. HoffmannOrphanet 2021 · DOI

Abstract

The diagnostic journey for patients with rare diseases (RD) is often characterized by a "diagnostic odyssey"—a prolonged period of uncertainty, misdiagnosis, and uncoordinated care. The TRANSLATE-NAMSE project, funded by the German Federal Joint Committee, developed an integrated clinical pathway (CPW) to transform this odyssey into an organized and trackable route. This model serves as a tool for diagnosis, treatment coordination, and patient education. By implementing a generic, 23-step pathway across nine German centers, the project achieved a diagnostic yield of over 60% and significantly reduced the time to diagnosis.

Introduction

Rare diseases affect approximately four million individuals in Germany alone. Due to their complexity and clinical heterogeneity, these conditions often evade standard diagnostic protocols, leading to years of unnecessary testing and emotional distress for families. While advancements in genomic technologies like Whole Exome Sequencing (WES) offer hope, their integration into routine clinical practice requires a structured framework. The TRANSLATE-NAMSE project addressed this need by creating a generic Clinical Pathway (CPW) designed to streamline the diagnostic process and transition patients into long-term care.

The TRANSLATE-NAMSE Model: A Generic Clinical Pathway

Unlike traditional clinical pathways that are specific to a single disease, the TRANSLATE-NAMSE model is "generic." It provides a standardized framework for the process of reaching a diagnosis, allowing specific guidelines to be integrated once a diagnosis is suspected or confirmed.

Core Components

  • Structured 23-Step Flowchart: The pathway guides clinicians through every stage, from the initial suspicion of a rare disease (often triggered by newborn screening or specific clinical phenotypes) to confirmatory testing and the initiation of treatment.
  • Multidisciplinary Case Conferences: These conferences are the "backbone" of the model. They bring together a diverse group of experts—including clinical specialists, geneticists, and medical coordinators—to evaluate complex cases and integrate scientific evidence with clinical findings.
  • Innovative Diagnostics: The pathway includes a clear protocol for escalating to advanced genomic testing (WES or Whole Genome Sequencing) when standard diagnostic procedures fail to provide answers.
  • The Role of the Medical Coordinator: A dedicated coordinator acts as a moderator between disciplines, ensuring that the collective expertise of the team is harnessed efficiently and that the patient remains the focus of the process.

Implementation and Study Cohort

The model was validated through a multicenter study involving nine German centers for rare diseases. The study enrolled 611 individuals (587 of whom completed the pathway) across five key disease groups:

  1. Rare anemias
  2. Endocrinopathies
  3. Autoinflammatory diseases
  4. Primary immune deficiencies
  5. Inborn errors of metabolism

These groups were selected based on their inclusion in newborn screening programs or the specialized expertise of the participating centers.

Results: Breaking the Diagnostic Odyssey

The application of the CPW demonstrated significant improvements in both diagnostic yield and speed:

  • Diagnostic Yield: A definitive diagnosis was achieved for 62.8% of the cohort (369 out of 587 cases).
  • Efficiency of Genomic Testing: For patients requiring WES, the median time from first contact to a confirmed diagnosis was just 109 days. This represents a dramatic reduction compared to the multi-year averages typically reported in rare disease literature.
  • Diagnostic Methods: While 47% of patients were diagnosed using standard clinical procedures, 15.8% were diagnosed specifically through the innovative application of WES.
  • Identifying False Positives: The pathway also successfully identified 17.7% of cases (104 patients) as false positives, preventing unnecessary and potentially harmful lifelong treatments.

Discussion and Future Directions

The TRANSLATE-NAMSE project demonstrates that a structured, multidisciplinary approach can effectively navigate the complexities of rare disease diagnosis. Beyond its clinical utility, the pathway serves as a vital communication tool, providing transparency for families and a training framework for new clinicians.

However, several challenges remain for nationwide implementation. These include the limited accessibility of WES in routine care, the need for improved digital interoperability between hospital systems, and the requirement for comprehensive cost-effectiveness analyses. Future work may involve adapting this model for European Reference Networks (ERNs) to standardize care across the European Union, ensuring that every patient with a rare disease has access to a clear and efficient path to diagnosis and treatment.

Summary updated

Abstract

Our model is a tool to change the diagnostic odyssey into an organised and trackable route. It can also be used to inform patients and families about the stages of their individual route, to update health care providers only partially involved or attending specialised treatment and care, like the patient's or family's primary physician, and finally to train novices in the field.
BibTeX
@inproceedings{choukair2021integrated,
  author = {Daniela Choukair and Fabian Hauck and Markus Bettendorf and Heiko Krude and Christoph Klein and Tobias Bäumer and Reinhard Berner and Min Ae Lee‐Kirsch and Corinna Grasemann and Peter Burgard and Georg F. Hoffmann},
  title = {{An Integrated clinical pathway for diagnosis, treatment and care of rare diseases: model, operating procedures, and results of the project TRANSLATE-NAMSE funded by the German Federal Joint Committee}},
  booktitle = {Orphanet},
  year = {2021},
  doi = {10.1186/s13023-021-02092-w},
}
Figure